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Background: There is no available data on clinical outcome in patients with acute myocardial infarction (AMI)
complicated by cardiogenic shock who are supported by an intra-aortic balloon pump (IABP) in combination with
extracorporeal life support (ECLS).
Methods: We analysed 96 consecutive patients with AMI and complicating cardiogenic shock who were assisted
by an ECLS system between January 2004 and December 2011. The primary outcome was in-hospital mortality.
The secondary outcomes were the success rate of weaning from ECLS and the lactate clearance for 48 hours (%).
Results: A combination of IABP and ECLS was used in 41 (42.7%) patients. In-hospital mortality occurred for 51
patients (ECLS with IABP versus ECLS alone; 51.2% vs. 54.5%, p = 0.747). The success rate of weaning from ECLS was
similar between the two groups (63.4% vs. 58.2%, p = 0.604). Complications such as ischemia of a lower extremity or
bleeding at the ECLS insertion site (p = 0.521 and p = 0.667, respectively) did not increase when ECLS was combined
with IABP. Among patients who survived for 24 hours after intervention, lactate clearance was not significantly different
between patients who received ECLS alone and those who received ECLS with IABP (p = 0.918).
Conclusions: The combined use of ECLS and IABP did not improve in-hospital survival in patients with AMI
complicated by cardiogenic shock.
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The mortality rate for acute myocardial infarction (AMI)
complicated by cardiogenic shock appears to be un-
changed at about 40-50% after the introduction of pri-
mary percutaneous coronary intervention (PCI) and an
intra-aortic balloon pump (IABP) [1-3]. Accordingly, new
mechanical-assist devices are being developed to maintain
hemodynamic support in cardiogenic shock. Extracorpor-
eal life support (ECLS) can be placed percutaneously and
initiated quickly, making it helpful in emergencies [4].* Correspondence: sh1214.choi@samsung.com
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unless otherwise stated.ECLS, however, has an essential limitation: it is only able
to partially unload the left ventricle (LV), and LV afterload
may be high [5]. IABP may be an option to optimize
hemodynamic status during ECLS and to reduce afterload
and increase diastolic augmentation with an improvement
in coronary perfusion [6]. There is limited data, however,
about clinical outcomes of simultaneous IABP support
and ECLS in AMI patients complicated by cardiogenic
shock. Here, we report outcomes of this combination
therapy.Methods
Study population
We retrospectively reviewed our registry of patients with
ECLS between January 2004 and December 2011 (Figure 1).. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Study population. ECLS, extracorporeal life support; CMP, cardiomyopathy; AMI, acute myocardial infarction; IABP, intra-aortic balloon
pump; PCI, percutaneous coronary intervention.
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of Samsung Medical Center. Patients were enrolled for the
study if they presented with an AMI (with or without ST-
elevation) complicated by cardiogenic shock or in-hospital
arrest. A patient was diagnosed with cardiogenic shock if
their systolic blood pressure was less than 90 mmHg for
more than 30 minutes after correcting hypovolemia, hypox-
emia, and acidosis with maximal medical treatment. An ar-
rest was presumed to be of cardiac aetiology unless it was
known or likely to have been caused by non-cardiac cause.
We excluded patients with age >80 years, previous severe
neurologic damage, those who previously signed a “do-not-
resuscitate” order, and patients with irreversible organ fail-
ure who would not have received physiological benefits
from this treatment.
ECLS implantation
ECLS was performed when patients in cardiogenic shock
were unresponsive to the administration of vasopressors
after the correction of hypovolemia and hypoxemia or
when arrest was prolonged or recurrent. The decision to
implant ECLS, IABP, or both was determined by the experi-
enced interventional cardiologists in charge. When patients
with IABP deteriorated, we implanted ECLS therapy. All
patients were expected to undergo early revascularization
and to receive medical therapy in accordance with guide-
lines [7,8].A Capiox Emergency Bypass System (Capiox EBS™;
Terumo Inc., Tokyo, Japan) was used in all cases. This
system is composed of a portable controller with a back-
up battery, a disposable bypass circuit integrated with a
heparin-coated membrane oxygenator, and a centrifugal
pump. Device insertion was performed by percutaneous
cannulation using the Seldinger technique. Surgical can-
nulation using the cut-down method was performed in
difficult cases. Cannula sizes ranged from 14 to 21
French for the femoral artery and from 21 to 28 French
for the femoral vein. In the event of distal limb ischemia
after arterial cannulation, a catheter was inserted distal
to the cannulation site for limb perfusion. In patients re-
ceiving combined ECLS and IABP, a 40-ml intra-aortic
balloon was introduced via the femoral artery on the op-
posite side of the ECLS-inserted catheter. IABP support
was initiated using 1:1 electrocardiographic triggering
and was maintained until weaning from the ECLS.
Patient management under ECLS
We previously reported detailed management [9] in
which continuous unfractionated heparin was infused
intravenously to maintain an activated clotting time bet-
ween 180 and 220 sec. The initial revolutions per minute
of the ECLS device and use of vasoactive drug were ad-
justed in order to achieve an ideal cardiac index greater
than 2.2 L/min/body surface area (m2), central mixed
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pressure greater than 65 mmHg. Echocardiography
was performed daily to monitor cardiac function. If the
patient was hemodynamically stable and adequately
oxygenated, they were considered for ECLS weaning
when the flow rate was 1 L/min/m2 for four hours.
Successful weaning was defined as disconnection of
the patient from ECLS without reinsertion or death
within 24 hours. After that time, weaning from IABP
was achieved by reducing the trigger ratio. Termin-
ation of ECLS was considered, with the consent of the
family, when there was intractable multi-organ failure
or severe neurologic damage consistent with a vegeta-
tive state or brain death.
Data collection and outcome variables
The primary outcome of the study was in-hospital
mortality. To determine predictors of mortality, cli-
nical data was obtained through medical record review.
Detailed in-hospital data included age, gender, co-
morbidities, and laboratory and procedural findings.
Secondary outcomes included the success rate of
weaning from ECLS and the lactate clearance for
48 hours. Lactate level was measured from arterial or
venous blood samples. Lactate clearance for 48 hours
(%) was defined according to the following formula:
lactate clearance for 48 hours (%) = [(highest lactate
level in the initial six hours – lowest lactate level in the
first 24 to 48 hours)/highest lactate level in the initial
six hours] × 100. Safety outcomes included limb ische-
mia requiring surgical or interventional therapy, bleed-
ing requiring transfusion (decrease in haemoglobin
greater than 2.0 g/dL), stroke (identified by the occur-
rence of new neurologic symptoms with the evidence of
ischemia or haemorrhage on computed tomography),
and sepsis with clinical signs of infection and growth of
bacteria on blood culture.
Statistical analysis
All values are presented as number with percentage
for categorical variables and median with interquartile
range for continuous variables. Comparisons between
continuous variables were made using a t-test or Mann–
Whitney U test, as appropriate. Categorical data were
analysed using the Chi-square test or Fisher’s exact
test, as appropriate. Event-free survival curves were es-
timated by the Kaplan-Meier method and compared
using the log-rank test. Hazard rates were determined
by survival analysis using the Cox proportional hazards
model. In multivariable models, covariates included
those with a p value < 0.2 and those that were clinically
relevant. We selected the number of variables in each
multivariable model in order to have approximately
one variable for every ten patients so as to reduceoverfitting. All tests were two-tailed, and p < 0.05 was
considered statistically significant. SPSS version 20




Between January 2004 and December 2011, 96 patients
presented with AMI complicated by cardiogenic shock
and were enrolled in this study. IABP support was com-
bined with ECLS in 41 patients (ECLS/IABP group),
whereas 55 patients were supported by ECLS alone (ECLS
alone group). Baseline characteristics and comparisons be-
tween the ECLS/IABP group and the ECLS alone group
are shown in Table 1. Demographics and co-morbidities
were similar between the two groups. There were no sig-
nificant differences in the clinical course before initiation
of mechanical-assist devices between the two groups, ex-
cept for cardiopulmonary resuscitation (CPR). Sixty-one
(63.5%) patients underwent CPR just before ECLS place-
ment. There were fewer patients with cardiac arrest in the
ECLS/IABP group than in the ECLS alone group [20/41
(48.8%) vs. 41/55 (74.5%), P = 0.009].
PCI was used for revascularization in 78 (81.3%) pa-
tients. Ten (10.4%) patients underwent immediate bypass
surgery or PCI with subsequent bypass surgery. Medical
treatment was maintained in eight (8.3%) patients after
coronary angiography. Six patients did not receive revas-
cularization due to diffuse or distal coronary artery dis-
ease; two patients did not receive revascularization due to
cannulation failure. Seven of these eight patients passed
away.
Clinical outcomes
Observed clinical outcomes are shown in Table 2. The
in-hospital mortality was similar among patients in the
ECLS/IABP group and the ECLS alone group (51.2%
and 54.5%, respectively; hazard ratio with additional
IABP, 0.8; 95% confidence interval [CI] 0.457-1.399; P =
0.434). The cumulative rates of survival at 30 days in the
ECLS/IABP group and the ECLS alone group were
53.9% and 53.1%, respectively (Figure 2). Additional
IABP had no significant impact on in-hospital mortality
in multivariate modelling after adjusting for age, sex,
CPR, ST elevation myocardial infarction, heart rate, left
ventricular ejection fraction, and treatment strategies
(hazard ratio 0.972; 95% CI 0.506-1.866; P = 0.932).
The success rates of weaning from ECLS were also
similar between the two groups (63.4% vs. 58.2%, P =
0.604). Among patients who survived for 24 hours or
more, there was no significant difference in lactate clear-
ance for 48 hours between the ECLS/IABP group and
the ECLS alone group. There were no significant differ-
ences between the ECLS/IABP group and the ECLS







Age, years 66 (57–74) 64 (54–75) 0.591
Male gender 31 (75.6) 43 (78.2) 0.767
Body mass index, kg/m2 24.0 (22.4-25.5) 22.8 (21.1-25.2) 0.251
Diabetes mellitus 24 (58.5) 35 (63.6) 0.612
Hypertension 21 (51.2) 25 (45.6) 0.576
Dyslipidemia 5 (12.2) 9 (16.4) 0.567
Current smoker 17 (41.5) 22 (40.0) 0.885
Previous myocardial infarction 7 (17.1) 6 (10.9) 0.383
Previous PCI 7 (17.1) 9 (16.4) 0.926
Previous bypass surgery 3 (7.3) 1 (1.8) 0.310
Known peripheral arterial
disease
4 (9.8) 3 (5.5) 0.456
Myocardial infarction 0.559
ST-elevation 26 (63.4) 38 (69.1)
Non-ST-elevation 15 (36.6) 17 (30.9)
Cardiopulmonary resuscitation 20 (48.8) 41 (74.5) 0.009
Systolic blood pressure,
mmHg
78 (70–83) 80 (70–82) 0.868
Diastolic blood pressure,
mmHg
49 (40–60) 50 (44–56) 0.906
Heart rate 113 (71–140) 92 (71–107) 0.285
Hemoglobin, g/dL 13.0 (10.6-14.8) 12.5 (10.3-14.4) 0.497
Creatinine, mg/dL 1.26 (1.07-1.78) 1.23 (0.97-1.75) 0.664
Lactate, initial, mmol/L 7.7 (2.7-13.1) 6.1 (3.4-9.5) 0.550
Left ventricular ejection fraction, % 30 (24–38) 40 (25–50) 0.109
Multi-vessel disease 33 (80.5) 36 (65.5) 0.105
Infarct-related artery 0.319
Left main 6 (14.6) 13 (23.6)
Left anterior descending 19 (46.3) 29 (52.7)
Left circumflex 7 (17.1) 4 (7.3)
Right coronary 9 (22.0) 9 (16.4)
Treatment strategies 0.056
PCI 33 (80.5) 45 (81.8)
Bypass surgery 7 (17.1) 3 (5.5)
Medical treatment 1 (2.4) 7 (12.7)
Use of vasopressor/inotropic
agent
41 (100) 54 (98.2) 1.000
Values are median (interquartile range) or n (%).
ECLS, extracorporeal life support; IABP, intra-aortic balloon pump; PCI, percutaneous
coronary intervention.
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gastrointestinal bleeding, stroke, or sepsis.
Discussion
We investigated whether additional IABP is associated
with improved in-hospital survival in patients with AMIand complicating cardiogenic shock who underwent
ECLS. The combined use of ECLS and IABP did not im-
prove in-hospital survival or tissue hypoperfusion. The
additional IABP insertion did not increase vascular com-
plications or bleeding.
An IABP improves coronary and peripheral perfusion
via diastolic balloon inflation and augments LV perform-
ance via systolic balloon deflation, with an acute decrease
in afterload [10]. The effects of IABP during ECLS, how-
ever, have not been evaluated sufficiently. An experimental
study suggested that IABP-induced pulsatility improves
coronary bypass graft flows during nonpulsatile ECLS
[11]. Another study proposed that adjunctive IABP im-
proves the myocardial oxygen supply–demand balance in
peripheral extracorporeal life support [12]. These benefits
of IABP might increase coronary flow during diastole and
compensate for limitations of ECLS, such as myocardial
oxygen consumption associated with increased LV after-
load. Consequently, the concomitant use of IABP might
improve in-hospital survival during ECLS management. In
our study of patients with AMI and complicating cardio-
genic shock, however, combined IABP support during
ECLS did not reduce in-hospital mortality. A recent study
in Korea also showed that the concomitant use of IABP
did not reduce hospital mortality despite an improved suc-
cess rate in weaning from ECLS [13]. The most likely ex-
planation about different successful weaning rate involves
patient selection. Our patients had a higher incidence of
cardiac arrest compared to that in the previous study
(63.5% vs. 31.6%). A large proportion of patients in their
study (46.6%) were enrolled for low cardiac output after
cardiac surgery, and it is therefore difficult to compare
their results directly to ours.
To the best of our knowledge, there have been no well-
designed trials to explain why there are no significant
differences between mortality in the two groups. We con-
sidered the possibility that coronary blood flow might not
increase enough to cause haemodynamic changes after
using IABP under continuous flow from ECLS into the
human circulating system. There were no significant dif-
ferences in haemodynamic variables, such as cardiac out-
put, between the patients supported by IABP and the
patients treated with medical therapy in a recent random-
ized trial, although that study was conducted without
ECLS management [14]. Furthermore, the IABP balloon
may cause intermittent aortic occlusion, which may di-
minish the blood flow from ECLS to the aortic root and
coronary arteries. An experimental study demonstrated
that, in the setting of cardiac arrest, the addition of IABP
to ECLS might worsen coronary blood flow [15].
Because lactate clearance early in hospital care may in-
dicate a resolution of global tissue hypoxia [16], we com-
pared the lactate clearance for 48 hours between the
ECLS/IABP group and the ECLS alone group to evaluate






In-hospital death 21 (51.2) 30 (54.5) 0.747
ECLS weaning success 26 (63.4) 32 (58.2) 0.604
Lactate clearance
for 48 hours, %*
65.2 (40.9-79.6) 65.3 (25.2-82.0) 0.918
Complications
Limb ischemia 6 (15.0) 5 (9.4) 0.521
ECLS site bleeding 9 (22.5) 10 (18.9) 0.667
Gastrointestinal
bleeding
9 (22.5) 6 (11.3) 0.147
Stroke 0 3 (7.5) 0.076
Sepsis 3 (7.5) 4 (7.5) 1.000
Values are median (interquartile range) or n (%).
ECLS, extracorporeal life support; IABP, intra-aortic balloon pump.
*Lactate clearance for 48 hours was available in 80 patients who survived at
least 24 hours after intervention.
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hypoperfusion during cardiogenic shock. Lactate clear-
ance for 48 hours, however, was similar regardless of the
combined use of IABP. This finding suggests that add-
itional IABP support is unlikely to be useful in the early
recovery from severe cardiogenic shock.
Our study had several limitations. First, it was a retro-
spective, observational study; therefore, confounding fac-
tors may have significantly affected our results. Hidden
biases for the initiation of mechanical-assist devices
might exist because the attending physician in chargeFigure 2 A comparison of survival between the ECLS/IABP group (n =
support; IABP, intra-aortic balloon pump.decided whether to use ECLS alone or with IABP. Fur-
thermore, the ECLS/IABP group included patients who
were initially supported by IABP alone and later also re-
ceived ECLS. Our hypothesis was that the effect of LV
unloading by IABP during ECLS might improve survival.
Therefore, patients were placed in the ECLS/IABP group
if they were supported by the IABP during ECLS, regar-
dless of the implantation order. Second, our registry did
not include pulmonary capillary wedge pressure measured
by pulmonary arterial catheter, LV size, or E/e’ measured
by echocardiography. This haemodynamic information
might support the hypothesis of IABP’s effect on LV
unloading. Third, performance of CPR, which has been re-
ported as an important predictor of mortality in patients
with severe cardiogenic shock [17,18], was significantly
different between the two groups. In addition, a larger
number of patients treated with only medical therapy with-
out revascularization were included in the ECLS alone
group, and a larger number of patients who had undergone
bypass surgery were included in the ECLS/IABP group. Ef-
forts were made to compensate for these differences in the
multivariable analysis, but we may not have been able to
overcome the differences. Fourth, our data included a large
number of patients who underwent CPR and thus showed
a higher mortality than in another recent randomized trial
and a registry of cardiogenic shock [3,19]. Even if there are
minor benefits of IABP support, additional effects might
not be evident in patients with very severe cardiogenic
shock. As there have been no other clinical studies regar-
ding the use of IABP during ECLS, our study provides the41) and the ECLS alone group (n = 55). ECLS, extracorporeal life
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A large registry study or randomized trial, however, is
needed for a more complete assessment of the role of
IABP during ECLS.
Conclusions
Additional use of IABP during ECLS did not improve in-
hospital survival or tissue perfusion in patients with AMI
complicated by cardiogenic shock.
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